PeptideCompareNMN tablet vs NAD+ injection — how the two routes compare.
NAD+ can be raised by giving a precursor such as NMN or by giving NAD+ directly. Here is how the two routes differ in biology, practicality and evidence.
- NMN and NAD+ injections target the same molecule by two different routes.
- NMN is orally available and converted to NAD+ inside cells by NMNAT enzymes; how it enters cells is still debated.
- Injected NAD+ is broken down and rebuilt inside cells, and infusions are reported to cause discomfort.
- The published human evidence base is broader for oral precursors than for direct NAD+ injection.
How your body makes NAD+ from NMN — step by step
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in every cell of your body, essential for energy metabolism, DNA repair, and sirtuin activation. Levels decline significantly with age — by your 50s, you may have less than half the NAD+ you had at 20.
How direct NAD+ injection differs
Direct NAD+ injection does raise blood NAD+ levels rapidly. It differs from the precursor route in several ways:
- Administration: IV NAD+ infusions are reported to cause discomfort — flushing, chest tightness, nausea — and are typically given slowly.
- NAD+ doesn't cross cell membranes easily: Injected NAD+ in the bloodstream must be broken down and rebuilt inside cells anyway. The precursor route is more biologically direct.
- Cost: Injections are priced per clinic session, while oral NMN is sold as a supplement, so the two are not priced or obtained in the same way.
- Practicality: Injections are periodic clinic sessions, whereas an oral product is used at home.
What human studies show
Human trials of oral NMN have measured increases in blood NAD+ across a range of intake levels. Study designs differ widely, so results are not directly comparable, and whether higher NAD+ translates into clinical benefit is still being studied.
Sources
- Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nature Metabolism, 2019. www.nature.com
- Reply to: Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nature Metabolism, 2019 — the original authors’ response, so both sides of the dispute are on the record. www.nature.com
- A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD+ decline. Cell Metabolism, 2018. www.sciencedirect.com